Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its…
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its…
Sign in to your account